Evidence map›Paper›PMID 38667288›Full record

ArticleCells2024

Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.

Daniel J Turnham, Manisha S Mullen, Nicholas P Bullock, Kathryn L Gilroy, Anna E Richards, Radhika Patel, Marcos Quintela, Valerie S Meniel, Gillian Seaton, Howard Kynaston and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Detection of Tumor Suppressor Genes Rare Variants: Findings From Neuroblastoma Using Next-Generation Sequencing.Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Daniel J TurnhamThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.ORCID 0000-0002-2540-7363
Manisha S MullenThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.
Nicholas P BullockThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.
Kathryn L GilroyCancer Research UK Scotland Institute, Glasgow G61 1BD, UK.
Anna E RichardsThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.ORCID 0009-0002-9430-1746
Radhika PatelDivision of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Marcos QuintelaThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.ORCID 0000-0002-9628-695X
Valerie S MenielThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.
Gillian SeatonThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.
Howard KynastonDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.
Richard W E ClarksonThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.
Toby J PhesseThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.ORCID 0000-0001-9568-4916
Peter S NelsonDivision of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Michael C HaffnerDivision of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
John N StaffurthDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.
Helen B PearsonThe European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK.ORCID 0000-0002-3284-0843
Cardiff University · GBUniversity of Washington · USCancer Research UK · GBCardiff and Vale University Health Board · GBFred Hutch Cancer Center · USThe University of Melbourne · AU

Funding

Defining and Targeting Lineage Transition Programs Operative in AR Pathway Independent Prostate CancerR01CA234715 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NELSON, PETER S · 2020 to 2024
$2.0M
Targeting Vulnerabilities Exposed by Cancer Treatment-Induced Lineage PlasticityR01CA266452 · NCI · FRED HUTCHINSON CANCER CENTER · PI PETER S NELSON · 2022 to 2026
$2.0M
Cancer Research UK A27894NCI NIH HHS R01 CA234715NCI NIH HHS R01 CA266452
6 · The paper itself

Abstract

As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC) that is deficient for androgen receptor (AR) and neuroendocrine (NE) markers has increased. These prostate cancer subtypes are typically refractory to AR-directed therapies and exhibit poor clinical outcomes. Only a small range of NEPC/DNPC models exist, limiting our molecular understanding of this disease and hindering our ability to perform preclinical trials exploring novel therapies to treat NEPC/DNPC that are urgently needed in the clinic. Here, we report the development of the CU-PC01 PDX model that represents AR-negative mCRPC with PTEN/RB/PSMA loss and

Indexed as

PiperazinesProstatic Neoplasms, Castration-ResistantReceptors, AndrogenAnimalsBenzamidesDisease Models, AnimalHumansMaleMiceNeoplasm MetastasisNitrilesPhenylthiohydantoinPhthalazinesXenograft Model Antitumor AssaysBenzamidesenzalutamideNitrilesolaparibPhenylthiohydantoinPhthalazinesPiperazinesReceptors, Androgenandrogen receptor (AR)castration-resistant prostate cancer (CRPC)double-negative prostate cancer (DNPC)neuroendocrine (NE)patient-derived xenograft (PDX)

Identifiers

PMID38667288
PMCPMC11049137
OpenAlexW4394768377

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.